In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...

At present no reports on glulisine use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved for clinical use in patients with Type 1 and Type 2 ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart) and Eli Lilly's Humalog (insulin lispro) – will be priced at no ...

Novo yesterday presented preliminary data which showed the formulation, O1338GT, is as effective as Sanofi’s insulin injectable Lantus in controlling blood glucose levels. But the Denmark ...

28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...